Genmab A/S ADR (GMAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
GMAB POWR Grades
- Sentiment is the dimension where GMAB ranks best; there it ranks ahead of 96.56% of US stocks.
- GMAB's strongest trending metric is Value; it's been moving down over the last 179 days.
- GMAB ranks lowest in Momentum; there it ranks in the 4th percentile.
GMAB Stock Summary
- GENMAB A's market capitalization of $28,372,420,542 is ahead of 91.99% of US-listed equities.
- With a price/sales ratio of 17.89, GENMAB A has a higher such ratio than 93.67% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for GENMAB A; that's greater than it is for just 9.45% of US stocks.
- Stocks that are quantitatively similar to GMAB, based on their financial statements, market capitalization, and price volatility, are UI, NOK, ERIC, HCM, and NVEC.
- Visit GMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.genmab.com.
GMAB Stock Price Chart Interactive Chart >
GMAB Price/Volume Stats
| Current price | $44.32 | 52-week high | $44.56 |
| Prev. close | $43.98 | 52-week low | $26.19 |
| Day low | $44.14 | Volume | 155,300 |
| Day high | $44.56 | Avg. volume | 627,075 |
| 50-day MA | $37.82 | Dividend yield | N/A |
| 200-day MA | $34.81 | Market Cap | 29.18B |
Genmab A/S ADR (GMAB) Company Bio
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US. (Source:Wikipedia)
Latest GMAB News From Around the Web
Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsCompany Announcement COPENHAGEN, Denmark; November 23, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish tradin |
15 Biggest European Pharmaceutical CompaniesIn this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […] |
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority TagThe FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL. |
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabCompany Announcement COPENHAGEN, Denmark; November 21, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 11,608 restricted stock units to members of the Board of Directors and employees of the Company as well as the Company’s subsidiaries and 9,057 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK |
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)COPENHAGEN, Denmark, November 21, 2022--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target ac |
GMAB Price Returns
| 1-mo | 15.42% |
| 3-mo | 26.12% |
| 6-mo | N/A |
| 1-year | 13.12% |
| 3-year | 88.12% |
| 5-year | 132.82% |
| YTD | 12.03% |
| 2021 | -2.71% |
| 2020 | 82.09% |
| 2019 | 35.54% |
| 2018 | -0.61% |
| 2017 | -0.04% |
Loading social stream, please wait...